Twist Bioscience launches circulating tumor DNA reference standard, suitable for the development of liquid biopsy analysis

South San Francisco, California, USA--(Business Wire)--December 7, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers A successful company, the company announced the launch of the Twist cfDNA pan-cancer reference standard, a high-quality standardized control that can be used for the development and continuous monitoring of liquid biopsy tests to detect cancer through blood samples

Liquid biopsy testing is a promising and evolving field in clinical oncology, which relies on NGS-based circulating tumor DNA (ctDNA) analysis

Florian Battke, Head of Development Department of CeGaT GmbH, Germany, said: "With the increase in clinical validation experiments of liquid biopsy, a true ctDNA pan-cancer reference standard, rather than the few variants that are widely used today, will improve the ability of liquid biopsy to detect specific Accuracy in terms of oncogenes and mutations

The Twist cfDNA pan-cancer reference standard material is composed of synthetically designed variant sequences and background DNA.

Researchers can use this reference standard to assist the development of liquid biopsy analysis to establish the limit of detection (LoD) for specific cancer variants, and use it as a control to track the quality of the NGS analysis process to ensure the fidelity of the analysis process Degrees

Twist cfDNA pan-cancer reference standards can be used in liquid biopsy procedures with Twist library preparation kit and Twist mechanical fragmentation kit to maximize efficacy, and provide a large number of different clinically relevant mutations, combined with first-class mutation synthesis methods, As well as excellent control over the frequency of specific target alleles, its form highly mimics the size distribution and fragmentation characteristics of cfDNA

Dr.

When developing and validating analyses, the use of appropriate reference materials is essential to assess the complexity and biological content of DNA in liquid biopsy samples

When demonstrating the limit of detection (LoD) of ultra-sensitive liquid biopsy analysis based on NGS, the use of an accurate quantitative ctDNA control is the key

About Twist Bioscience

Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering